Shares of Pulmonx Corp. (LUNG), a commercial-stage medical technology company, are trading at a significant discount to their 52-week high, priced around $6.
The company is a provider of minimally invasive treatments for patients with severe emphysema, a form of chronic obstructive pulmonary disease, and its marketed products include Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System and LungTraX Platform (which is called the StratX Platform in international markets).
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.